LCK and chronic myelogenous leukemia, BCR-ABL1 positive: It has been demonstrated that the tyrosine kinase inhibitor Dasatinib, an FDA-approved treatment for Philadelphia chromosome-positive chronic myeloid leukemia (CML) and ALL, inhibits LCK and thereby prevents the phosphorylation of CD3ζ and ZAP70 (96).